TYK MEDICINES-B

TYK Medicines opened higher but pulled back during the session, hitting an intraday high of HKD 6.74 before settling at HKD 6.46, up 2.54% from the previous close of HKD 6.30, with total turnover of approximately HKD 31.29 million. The positive move may be linked to the announcement of an extraordinary general meeting on July 30, drawing attention to potential governance changes. However, the stock remains 74.9% below its 52-week high of HKD 25.75 and has fallen 50% year-to-date, while trading below its 60-day moving average of HKD 8.573, with only a 20.75% cushion above the 52-week low. The company narrowed its full-year loss to RMB 300 million with stable R&D spending, secured a drug production license, and had multiple novel cancer programs selected for the AACR meeting, indicating gradual fundamental improvement, though it remains unprofitable with a PB ratio of 7.74.